AABIP 2022 Presentation
Presented by: Dr. Sonali Sethi, Dr. Bill Bulman
Speakers will review the Percepta Genomic Sequencing Classifier (GSC) performance in lung nodule patient management and the role of the Envisia Genomic Classifier in the diagnosis and prognosis of ILD patients.
In this webinar speakers review published data on the Envisia Genomic Classifier, updates from the recent IPF/PPF clinical guideline, and how they have integrated the classifier into their practice.
Envisia detects genomic UIP pattern to improve ILD diagnostic and prognostic confidence.
Percepta GSC stratifies the risk of lung cancer to guide patient management for when bronchoscopy is inconclusive.
Percepta Nasal Swab brings genomic objectivity to lung nodule risk assessment with a simple, non-invasive tool.
Percepta Genomic Atlas guides personalized treatment earlier in lung cancer diagnosis.
Transform uncertainty into confidence
Veracyte offers a suite of actionable genomic tests that can offer greater confidence and clarity at every step of your lung cancer and interstitial lung disease patient management.